3//SEC Filing
NEA 16 GP, LLC 3
Accession 0001209191-20-005442
CIK 0001701541other
Filed
Jan 28, 7:00 PM ET
Accepted
Jan 29, 8:08 PM ET
Size
9.9 KB
Accession
0001209191-20-005442
Insider Transaction Report
Form 3
New Enterprise Associates 16, L.P.
10% Owner
Holdings
Series B Preferred Stock
→ Common Stock (2,176,957 underlying)Series C Preferred Stock
→ Common Stock (471,800 underlying)
NEA 16 GP, LLC
10% Owner
Holdings
Series B Preferred Stock
→ Common Stock (2,176,957 underlying)Series C Preferred Stock
→ Common Stock (471,800 underlying)
NEA Partners 16, L.P.
10% Owner
Holdings
Series B Preferred Stock
→ Common Stock (2,176,957 underlying)Series C Preferred Stock
→ Common Stock (471,800 underlying)
Footnotes (3)
- [F1]Each share of Series B Preferred Stock is convertible into shares of the Issuer's Common Stock on a one-for-3.01581 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3. The Series B Preferred Stock has no expiration date.
- [F2]The shares are directly held by New Enterprise Associates 16, L.P. ("NEA 16"), and indirectly held by NEA Partners 16, L.P. ("NEA Partners"), the sole general partner of NEA 16, NEA 16 GP, LLC ("NEA 16 GP"), the sole general partner of NEA Partners 16, and the individual managers of NEA 16 GP (NEA Partners 16, NEA 16 GP and the individual managers of NEA 16 GP, together, the "Indirect Reporting Persons").The individual managers of NEA 16 GP are Forest Baskett, Ali Behbahani, Carmen Chang, Anthony A. Florence, Jr., Mohamad Makhzoumi, Josh Makower, David M. Mott, Scott D. Sandell, Peter W. Sonsini and Paul Walker. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares of the Issuer held by NEA 16 in which the Indirect Reporting Persons have no pecuniary interest.
- [F3]Each share of Series C Preferred Stock is convertible into shares of the Issuer's Common Stock on a one-for-3.01581 basis. Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3. The Series C Preferred Stock has no expiration date.
Documents
Issuer
Black Diamond Therapeutics, Inc.
CIK 0001701541
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001712882
Filing Metadata
- Form type
- 3
- Filed
- Jan 28, 7:00 PM ET
- Accepted
- Jan 29, 8:08 PM ET
- Size
- 9.9 KB